Gene Editing Technologies to Target HBV cccDNA

Area of Science:

• Hepatology and Virology
• Molecular Biology
• Gene Therapy

Background:

• Chronic Hepatitis B virus (HBV) infection is a major global health concern, leading to cirrhosis and liver cancer.
• Current antiviral therapies suppress HBV replication but fail to eliminate intrahepatic covalently closed circular DNA (cccDNA), causing viral persistence.
• Life-long treatment is necessary to manage chronic HBV due to the presence of cccDNA, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the latest advancements in gene editing and related technologies for targeting HBV DNA.
• To explore the potential of these approaches in reducing, silencing, or eradicating HBV cccDNA in infected hepatocytes.
• To address the need for curative therapies that prevent HBV reemergence after treatment cessation.

Main Methods:

• Review of current literature on gene editing tools (e.g., CRISPR-Cas) and their application to HBV.
• Analysis of strategies for delivering gene editing components to hepatocytes.
• Discussion of methods to assess the efficacy of gene editing in targeting HBV cccDNA.

Main Results:

• Gene editing technologies show promise in directly targeting and modifying HBV DNA, including cccDNA.
• Successful reduction or silencing of cccDNA has been demonstrated in preclinical models.
• These approaches offer a potential pathway to a functional cure for chronic HBV infection.

Conclusions:

• Gene editing represents a promising therapeutic strategy for chronic HBV infection.
• Targeting HBV cccDNA with gene editing could lead to a functional cure, eliminating the need for long-term treatment.
• Further research and clinical development are crucial to translate these findings into effective therapies.